{"id":"injection-of-apomorphine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Nausea"},{"rate":"10-30","effect":"Yawning"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Somnolence"},{"rate":"5-15","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Apomorphine acts as a non-selective dopamine receptor agonist, primarily binding to D2 and D3 dopamine receptors. In Parkinson's disease, dopamine-producing neurons degenerate, leading to motor dysfunction; apomorphine bypasses this deficit by directly activating dopamine receptors, thereby restoring dopaminergic signaling and alleviating motor symptoms such as tremor, rigidity, and bradykinesia.","oneSentence":"Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:31.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease, acute motor fluctuations and 'off' episodes"}]},"trialDetails":[{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT04957095","phase":"NA","title":"Motor Network Physiology","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-02-18","conditions":"Parkinson Disease, Essential Tremor","enrollment":120},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT04879134","phase":"PHASE2, PHASE3","title":"Apomorphine Effects on Pain in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-02-28","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT00758368","phase":"PHASE2","title":"Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00955318","phase":"PHASE3","title":"Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":58},{"nctId":"NCT01063621","phase":"PHASE3","title":"Extended Long-Term Safety Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01058291","phase":"PHASE3","title":"Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT01504178","phase":"PHASE3","title":"Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":28},{"nctId":"NCT00200512","phase":"PHASE2, PHASE3","title":"Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-09","conditions":"Parkinson Disease","enrollment":16},{"nctId":"NCT00200525","phase":"PHASE3","title":"Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-07","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT00145171","phase":"PHASE3","title":"A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-02","conditions":"Parkinson Disease","enrollment":56},{"nctId":"NCT00142545","phase":"PHASE3","title":"Long Term Safety and Efficacy of SC Apomorphine in Treatment of \"Off\" Episodes in Late-Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-07","conditions":"Parkinson Disease","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"injection of apomorphine","genericName":"injection of apomorphine","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease. Used for Parkinson's disease, acute motor fluctuations and 'off' episodes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}